[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612637":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":25,"sex":31,"minAge":32,"maxAge":7,"enrollmentInfo":33,"targetDuration":7,"studyType":36,"phases":7,"briefSummary":37,"conditions":38,"keywords":41,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":7},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","low-fat diet, supplements, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, or other lipid-lowering agents","Low-Fat Diet Typical components: Increased fruits, vegetables, whole grains, lean proteins, and limited fried or processed foods.\n\nSupplements Non-prescription substances that can help reduce cholesterol, often used alongside diet or drugs. Plant sterols\u002Fstanols: Reduce cholesterol absorption in the intestine.\n\nStatins The first-line pharmacological treatment for high cholesterol. Mechanism: Inhibit HMG-CoA reductase, the key enzyme in cholesterol synthesis in the liver.\n\nEzetimibe A cholesterol absorption inhibitor. Mechanism: Blocks intestinal absorption of dietary and biliary cholesterol.\n\nBempedoic Acid A newer oral lipid-lowering drug. Mechanism: Inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway.\n\nPCSK9 Inhibitors Monoclonal antibodies or siRNA therapies given by injection every 2-4 weeks (or biannually for inclisiran).\n\nFibrates Drugs that primarily lower triglycerides and can modestly raise HDL cholesterol.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Giovanni Frisullo, MD, PhD","CONTACT","0630156321","giovanni.frisullo@policlinicogemelli.it",{"type":20,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Frisullo Giovanni","MD, PhD","100612637","coast-study---cholesterol-optimization-after-stroke-100612637",false,"NCT07256171","COAST Study - Cholesterol Optimization After Stroke","Cholesterol Optimization After Stroke: a Multicenter Prospective Study on LDL Cholesterol Control in Patients With Acute Stroke.","COAST","Inclusion Criteria:\n\n* • Recent acute cerebrovascular event, defined as a confirmed diagnosis of ischemic stroke, hemorrhagic stroke, or TIA occurring less than 30 days prior to enrollment.\n\n  * Availability of a baseline measured LDL cholesterol value (direct or calculated) at the time of the index event or close to it.\n  * Patients for whom, in routine clinical practice, a lipid-lowering therapy has been indicated and prescribed for secondary prevention (low-fat diet, supplements, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, or other lipid-lowering agents).\n  * Written informed consent obtained and signed by the patient before inclusion. If the patient is unable to provide consent autonomously (e.g., due to aphasia, impaired consciousness, etc.), informed consent will be obtained from a legal representative or proxy, in accordance with applicable regulations.\n\nExclusion Criteria:\n\n* • Comorbidities or conditions preventing 3-month follow-up: e.g., terminal oncological disease with life expectancy \\\u003C3 months, severe cognitive impairment (e.g., advanced dementia), or other conditions that make it impossible to obtain follow-up information; inability to contact the patient after discharge (e.g., non-resident foreign patient or lacking telephone contacts).\n\n  * Any other clinical, psychological, or social condition that, in the investigator's judgment, may compromise the patient's ability to adhere to the study or the reliability of the collected data.","ALL","18 Years",{"count":34,"type":35},500,"ESTIMATED","OBSERVATIONAL","This study (acronym COAST Trial) is a multicenter observational registry aiming to document: patients' adherence and persistence to lipid-lowering therapy prescribed for secondary prevention; the proportion of patients achieving LDL cholesterol therapeutic targets at 3 months; the incidence of cerebrovascular recurrence and mortality at 90 days, as well as the occurrence of any adverse effects from these therapies. This information will provide a snapshot of post-stroke\u002FTIA lipid-lowering management across centers and identify areas for improvement, offering useful data to optimize secondary prevention strategies in everyday clinical practice.",[39,40],"Stroke (CVA) or Transient Ischemic Attack","Cerebral Hemorrhage",[42,43,44,45,46,47,48,49,50],"LDL cholesterol","lipid-lowering agents","statins","ezetimibe","bempedoic acid","PCSK9 inhibitors","stroke","cerebral hemorrhage","transient ischemic attack","NOT_YET_RECRUITING","2025-11-20",{"date":54,"type":55},"2025-12-01","ACTUAL",{"date":57,"type":35},"2026-01-01",{"date":59,"type":35},"2026-12-31",{"name":5,"class":6}]